Publications

Dr Stacy Loeb has more than 350 peer- reviewed publications focusing primarily on prostate cancer, as well as men's health, drug safety and the use of social media in medicine. Click on the button's below to view Dr Loeb's publications by topic.

Prostate Cancer

PSA Screening ▼

Biomarkers ▼

Genetics ▼

Key Papers

Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

In light of numerous conflicting recommendations about prostate cancer screening, in August 2013 a multidisciplinary group convened in Melbourne, Australia to create consensus practice guidelines. Key areas of consensus are that level 1 evidence shows that prostate cancer screening saves lives among men ages 50-69, but that biopsy decisions should be made using PSA as part of a multivariable approach and that diagnosis must be uncoupled from treatment.

Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

This study reviews the published literature showing that baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Baseline PSA testing should be offered to young men for risk stratification and to guide screening protocols.

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?”

Journal of Clinical Oncology January 2011; 29: 464.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Although number needed to screen (NNS) and number needed to treat (NNT) are useful statistics to assess the benefits and harms of an intervention, in a survival study setting such as the European Randomized Study of Screening for Prostate Cancer (ERSPC), NNS and NNT are time specific, and reporting values at one time point may lead to misinterpretation of results. We developed a model predicting that the NNS in this trial would decrease from 837 at year 10 to 503 at year 12, and NNT would decrease from 29 to 18.

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?”

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

Men ages 75-80 with PSA levels <3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that PSA testing might be safely discontinued for these men.

Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

In the general US population, the median PSA level is 0.7 ng/ml in the 40’s and 0.9 ng/ml in the 50’s. Young men with a baseline PSA level above the age-specific median are at significantly greater risk of future prostate cancer diagnosis and aggressive disease. Baseline PSA at a young age is a stronger predictor of prostate cancer than race, family history or digital rectal examination.

Reviews/Editorials

Loeb S.

“Will Changes to Prostate Cancer Screening Guidelines Preserve Benefits and Reduce Harms?”

European Urology 2016 April epub. PMID: 27090973.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27090973

Loeb S.

“Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening.”

Journal of Clinical Oncology 2016 Jun 20 epub. PMID: 27325846.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27325846

Loeb S, Lilja H, Vickers A.

“Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.”

Current Opinion in Urology 2016 Jun 3 epub. PMID: 27262138

Link: http://www.ncbi.nlm.nih.gov/pubmed/27262138

Loeb S. Editorial Comment on

“Trends in Prostate Specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments from 2000 to 2012.”

Urology 2015; 86: 504-5.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26282019

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379

Loeb S, Cooperberg MR.

“Early Detection of Prostate Cancer.”

Urological Clinics of North America 2014 May epub. PMID: 24725496

Link: http://www.ncbi.nlm.nih.gov/pubmed/24725496

Vellekoop A and Loeb S.

“Update of Randomized Trials for Prostate Cancer Screening.”

Reviews in Urology 2013; 15: 37-9. PMID: 23671404

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651541/

Loeb S

“Use of Baseline Prostate-Specific Antigen Measurements to Personalize Prostate Cancer Screening.”

European Urology May 2012: 61: 875-6. PMID:22154726.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22154726

Roobol MJ, Bangma CH, Loeb S.

“Prostate-specific antigen screening can be beneficial to younger and at-risk men.”

CMAJ, May 2012 epub. PMID: 22566532.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537779/

Loeb S, Carlsson S, and Braithwaite RS.

“Prostate Cancer: Modeling the Outcomes of Prostate Cancer Screening.”

Nature Reviews Urology, March 2012; 13: 183-5. PMID: 224106678.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22410678

Loeb S and Catalona WJ.

“PSA Should Drive Doing Prostate Biopsies.”

Urologic Oncology: Seminars and Original Investigations Jan-Feb 2012; 30: 1-2. PMID: 21458316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21458316

Loeb S, Trock BJ.

“Re: Randomized Prostate Cancer Screening Trial: 20 Year Follow-up.”

European Urology 2011; 60: 1306. PMID: 22054407.

Link: http://www.europeanurology.com/article/S0302-2838%2811%2900989-4/fulltext/re-randomised-prostate-cancer-screening-trial-20-year-follow-up

Loeb S.

“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622

Loeb S.

“Invited Editorial Comment Re: Variable Prostate-Specific Antigen Management Patterns by Nonurologist Providers at a Tertiary Medical Center.”

Urology August 2011; 78: 248. PMID: 21820564.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21820564

Loeb S.

“Use of Empiric Antibiotics in the Setting of an Increased Prostate Specific Antigen: Pro.”

Journal of Urology June 2011; 186: 17. PMID: 21571331.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21571331

Loeb S and Catalona WJ

“Prostate-specific antigen screening: pro.”

Current Opinion in Urology, May 2010; 20: 185.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20224413

Loeb S and Catalona WJ.

“Prostate Cancer: Utility of the Riskindicator Model in Screening.”

Nature Reviews Urology, April 2010; 7: 184.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20383184

Loeb S and Partin AW.

“What is the true mortality benefit of prostate-specific antigen screening?”

Reviews in Urology, Winter 2010; 12: 66.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859145/

Loeb S and Carter HB.

“Limitations and Use of PSA Derivatives in the Screening and Risk Stratification of Prostate Cancer.”

Urologic Oncology: Seminars and Original Investigations, Nov-Dec 2009; 27: 583.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19879470

Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

Primary Care Clinics of North America, September 2009; 36: 603.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19616157

Loeb S and Partin AW.

“Randomized Trials of Prostate Cancer Screening.”

Reviews in Urology, Summer 2009; 11: 179.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777067/

Loeb S and Catalona WJ.

“What is the Role of Digital Rectal Examination in Men Undergoing Serial Screening of Serum PSA?”

Nature Clinical Practice Urology, February 2009; 6: 68.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19139742

Loeb S, Gashti SN, and Catalona WJ.

“Exclusion of Inflammation in the Differential Diagnosis of an Elevated Prostate-Specific Antigen (PSA).”

Urologic Oncology: Seminars and Original Investigations, Jan-Feb 2009; 27: 64.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19111800

Loeb S and Catalona WJ.

“Diagnosis and Treatment of Prostate Cancer. Beyond the controversy over whether and whom to screen, the appropriate method of screening is also subject to debate.”

Medical Economics, December 2008; 85: 36.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19209648

Catalona WJ and Loeb S.

“Commentary on the Recommendations of The American College of Preventive Medicine on Prostate Cancer Screening.”

Medscape Urology (online)

Loeb S and Catalona WJ.

“What to do with an abnormal PSA test.”

The Oncologist, March 2008; 13: 299.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18378540

Catalona WJ and Loeb S.

“PSA Is an Effective Marker for Prostate Cancer.”

AUANews, January 2007 (Part 1) and February 2007 (Part 2)

Link:

Loeb S and Catalona WJ.

“Advances in Prostate Cancer Testing.”

Clinical Laboratory News, March 2007; 33: 12.

Loeb S and Catalona WJ.

“PSA as a Screening Test for Prostate Cancer.”

ACP Observer, April 2007

Loeb S and Catalona WJ.

“Prostate cancer screening: Where are we now?”

Contemporary Urology, May 2007

Link:

Catalona WJ and Loeb S.

“More Effective Use of PSA”

Urologic Oncology: Seminars and Original Investigations, May-June 2006; 24: 177.

Catalona WJ, Loeb S, and Han M.

“Viewpoint: Expanding Prostate Cancer Screening.”

Annals of Internal Medicine, March 2006; 144: 441.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16549857

Key Papers

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

“The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer.”

Journal of Urology 2014 Nov 15 epub. PMID:25463993

Link: http://www.ncbi.nlm.nih.gov/pubmed/25463993

Among men from the US FDA registration trial, we found that the Prostate Health Index was a better predictor of clinically significant prostate cancer compared to any of its component parts (total, free or -2proPSA). At the 90% sensitivity cut point for phi (a score less than 28.6), 30% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free PSA.

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

“Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.”

BJU International. 2012 Feb;109(4):508-13. PMID: 22296334

Link: http://www.ncbi.nlm.nih.gov/pubmed/22296334

Sustained rises in PSA indicate a significantly greater risk of prostate cancer, particularly high-grade disease. Men with 2 successive PSA velocity measurements >0.4 ng/ml/year (a “risk count” of 2) have an 8-fold increased risk of prostate cancer and 5.4-fold increased risk of Gleason 8-10 disease on biopsy compared to those with ≤1 serial PSAV exceeding 0.4 (risk count 0-1), adjusting for age and PSA level. Compared to PSA alone, PSA velocity risk count may reduce unnecessary biopsies and overdiagnosis of low-risk prostate cancer

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA.

“A Multicenter Study of [-2] Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.”

Journal of Urology May 2011; 185: 1650. PMID: 21419439.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21419439

This prospective, multicenter US trial led to the FDA approval of the Prostate Health Index (phi) in 2012. Phi is a new serum marker test combining total, free and -2proPSA. Among 892 men undergoing prostate biopsy at PSA levels of 2-10 ng/ml, phi was more specific for prostate cancer than either total or free PSA.

Reviews/Editorials

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance. “

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029c

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Loeb S, Dani H.

“Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268

Dani H, Loeb S.

“The Role of Prostate Cancer Biomarkers in Undiagnosed Men.”

Current Opinion Urology 2017; 27: 210-216. PMID 28212119

Link: https://www.ncbi.nlm.nih.gov/pubmed/28212119

Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28661898

Lepor A, Catalona WJ, Loeb S.

“The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics North America.”

2016 Feb;43(1):1-6. PMID: 26614024

Link: http://www.ncbi.nlm.nih.gov/pubmed/26614024

Loeb S, Lilja H, Vickers A.

“Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.”

Current Opinion in Urology 2016 Jun 3 epub. PMID: 27262138

Link: http://www.ncbi.nlm.nih.gov/pubmed/27262138

Loeb S.

“Prostate Biopsy Decisions: One Size Fits All Approach with Total PSA is Out and a Multivariable Approach with the Prostate Health Index is In.”

BJU International 2015 June epub. PMID: 26054000.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26054000

Loeb S.

“Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that PHI consistently outperforms PSA across diverse populations.”

BJU International 2015; 115: 500. PMID: 25808708

Link: http://www.ncbi.nlm.nih.gov/pubmed/25808708

Loeb S.

“Prostate cancer: Predicting prostate biopsy results- PCA3 versus phi.”

Nature Reviews Urology 2015 epub Feb 3. PMID: 25644161

Link: http://www.ncbi.nlm.nih.gov/pubmed/25644161

Lundon D, Loeb S.

“Prostate-Specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.”

Reviews in Urology 2014; 16: 154. PMID: 25337050.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191640/

Loeb S. Editorial Comment on

“Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less”

Urology 2014; 84: 1167. PMID: 25443924.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25443924

Loeb S, Catalona WJ.

“The Prostate Health Index: A New Test for the Detection of Prostate Cancer.”

Therapeutic Advances in Urology 2014; 6: 74. PMID: 24688603

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943368/

Loeb S.

“Editorial Comment on: A Commentary on PSA Velocity and doubling time for clinical decisions in prostate cancer”

Urology 2014; 83: 596. PMID: 24581522

Link: http://www.ncbi.nlm.nih.gov/pubmed/24581522

Loeb S. Editorial Comment on

“Prostate-Specific Antigen Density: Toward a Better Cutoff to Identify Better Candidates for Active Surveillance.”

Urology 2014; 84: 371.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24925831

Loeb S.

“Prostate Health Index (PHI): Golden Bullet or Just Another Prostate Cancer Marker?”

European Urology epub 2013 Feb 14. PMID: 23453055

Link: http://www.ncbi.nlm.nih.gov/pubmed/23453055

Loeb S.

“Prostate Cancer: Prostate Health Index- Improving Screening in Men with a Positive Family History.”

Nature Reviews in Urology 2013; 10: 497

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943368/

Loeb S, Carter HB.

“Point: Impact of Prostate-Specific Antigen Velocity on Management Decisions and Recommendations.”

Journal of the National Comprehensive Cancer Network 2013; 11: 281. PMID: 23486454

Link: http://www.ncbi.nlm.nih.gov/pubmed/23486454

Loeb S.

“An Examination of the Dynamic Changes in Prostate-Specific Antigen Occurring in a Population-Based Cohort of Men Over Time.”

BJU International August 2012; 110: 381-2. PMID: 22313542.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22313542

Loeb S.

“Editorial comment re: Longitudinal Changes of Benign Prostate-Specific Antigen and [-2]ProProstate-Specific Antigen in Seven Years in a Community-Based Sample of Men.”

Urology, March 2012; 79: 661. PMID: 22386421.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22386421

Loeb S, Metter EJ, and Carter HB.

“Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection.”

Journal of the National Cancer Institute November 2011; 103: 1636. PMID: 21926375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21926375

Loeb S.

“Prediction of Outcomes After Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy Gleason Score ≥8 Via Contemporary Multi (≥12)-Core Prostate Biopsy.”

BJU International 2011; 108: 222. PMID: 21718432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21718432

Loeb S. Editorial comment re:

“Prostate Specific Antigen Velocity per Prostate Volume: A Novel Tool for Prostate Biopsy Prediction.”

Urology 2011; 78: 879. PMID: 21982006

Link: http://www.ncbi.nlm.nih.gov/pubmed/21982006

Loeb S and Carter HB.

“Should prostate-specific antigen velocity be abandoned?”

Asian Journal of Andrology 2011; 12: 359. PMID: 21499277.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739355/

Loeb S.

“Editorial Comment Re: Evaluation of Prostate Specific Antigen Acceleration for Prostate Cancer Diagnosis.”

Journal of Urology March 2011; 185: 826. PMID: 21239022.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21239022

Loeb S and Partin AW.

“PCA3 Urinary Biomarker for Prostate Cancer.”

Reviews in Urology Fall 2010; 12: e205. PMID: 21234266.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020285/

Tosoian J and Loeb S.

“PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.”

TheScientificWorldJOURNAL: TSW Urology October 2010; 10: 1919–1931.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20890581

Loeb S and Carter HB.

“Limitations and Use of PSA Derivatives in the Screening and Risk Stratification of Prostate Cancer.”

Urologic Oncology: Seminars and Original Investigations, Nov-Dec 2009; 27: 583.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19879470

Loeb S.

“Prostate Cancer: Is PSA Velocity Useful?”

Nature Reviews Urology, June 2009; 6: 305.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19498408

Loeb S and Carter HB.

“Words of Wisdom: Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.”

European Urology, February 2009; 55: 523.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19606535

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB.

“The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.”

European Urology, November 2008 54: 978.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2603630/

Makarov DV, Loeb S, Getzenberg RH, and Partin AW.

“Biomarkers for Prostate Cancer.”

Annual Reviews in Medicine, October 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18947298

Loeb S.

“Does PCA3 Help Identify Clinically Significant Prostate Cancer?”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18684556

Loeb S and Catalona WJ.

“Cancer Biomarkers: Discovery and Validation.”

Cancer Letters, January 2007

Key Papers

Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O’Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

The 2019 Philadelphia Prostate Cancer Consensus Conference was a multidisciplinary conference including experts and other stakeholders to create a series of recommendations surrounding germline genetic evaluation for prostate cancer.

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.

“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/

Correcting the PSA level for a man’s genotype could potentially reduce the number of men referred for prostate biopsy by up to 20%, while reducing the number of potentially delayed diagnoses by 3% for men with genetically lower PSA levels.

Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.”

Cancer Causes Control 2012; December epub. PMID: 23266834.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

First-generation immigrants to Sweden (a high risk country for prostate cancer) have a lower risk of all stages of prostate cancer compared to native-born men, especially men who immigrated to Sweden recently or at an older age.

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

Reviews/Editorials

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379

Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

“Screening for Familial and Hereditary Prostate Cancer“.

International Journal of Cancer.

2015 Dec 5 epub. PMID: 26638190

Link: http://www.ncbi.nlm.nih.gov/pubmed/26638190

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/

Loeb S.

“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

Epidemiology ▼

Prostate Biopsy ▼

Staging ▼

Key Papers

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

This study examined effect modification by environmental factors of the association between single nucleotide polymorphisms with prostate cancer risk. Among men at high risk for prostate cancer based on their genotype, use of selenium was associated with a lower risk of advanced prostate cancer, while aspirin, ibuprofen and vegetables were associated with lower risk of nonadvanced prostate cancer.

Reviews/Editorials

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159990

Mullins JK, Loeb S.

“Environmental exposures and prostate cancer.”

Urologic Oncology: Seminars and Investigations, March 2012; 30: 216. PMID: 22385992.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22385992

Mullins JK and Loeb S.

“Diabetes Mellitus and Prostate Cancer Risk.”

Expert Review of Endocrinology and Metabolism November 2010; 5: 787.

Loeb S and Partin AW.

“Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention.”

Reviews in Urology, Spring 2009; 11: 114.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725311/

Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

Primary Care Clinics of North America, September 2009; 36: 603.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19616157

Key Papers

Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, Stroup SP.

“An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy.”

Journal of Urology 2017 Mar 29 epub. PMID: 28363690

Link: https://www.ncbi.nlm.nih.gov/pubmed/28363690

This is an updated American Urological Association White Paper with guidance on the prevention and treatment of prostate biopsy complications.

Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, and Lotan Y.

“Systematic Review of Complications of Prostate Biopsy.”

European Urology 2013; June epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23787356

This systematic review of prostate biopsy complications found that hematuria and hematospermia are most common, but are typically mild and self-limiting. Severe rectal bleeding is uncommon. Despite antimicrobial prophylaxis, infectious complications are increasing over time and are the most common reason for hospitalization after biopsy. Pain may occur at several stages of prostate biopsy and can be mitigated by anesthetic agents and anxiety-reduction techniques. Up to 25% of men have transient LUTS after biopsy, and <2% have frank urinary retention, with slightly higher rates reported after transperineal template biopsy. Biopsy-related mortality is rare.

Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ.

“Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized Trial.”

European Urology June 2012; 61: 1110-4. PMID: 22244150

Link: http://www.ncbi.nlm.nih.gov/pubmed/22244150

Among men undergoing prostate biopsy in the European Randomized Study of Screening for Prostate Cancer (ERSPC), 4% developed a fever and 0.8% were admitted to the hospital. Although the risk of hospitalization for infection increased over time, the absolute frequency was low. Because this same trial showed that screening reduces advanced disease and prostate cancer death, the risk of biopsy-related complications should not dissuade healthy men with a sufficient life expectancy to benefit from early detection from undergoing an indicated prostate biopsy.

Loeb S, Carter HB, Berndt SI, Ricker W, and Schaeffer EM.

“Complications After Prostate Biopsy: Data From SEER-Medicare.”

Journal of Urology November 2011; 186: 1830. PMID: 21926375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21944136

This was the first paper to call attention to the increasing risk of hospitalization for infection after prostate biopsy in the United States. Careful patient selection for prostate biopsy is essential to minimize the potential downstream harms of prostate cancer screening, and this paper has been cited by numerous guidelines

Reviews/Editorials

Loeb S.

“When is a Negative Prostate Biopsy Really Negative? Repeat Biopsies in Detection and Active Surveillance.”

Journal of Urology 2017 epub. PMID 28110035

Link: https://www.ncbi.nlm.nih.gov/pubmed/28110035

Loeb S, Montorsi F, Catto JW.

“Future-Proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?”

European Urology 2015 epub. PMID: 25769986.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25769986

Loeb S. Editorial Comment on:

“For Single Dosing, Levofloxacin is Superior to Ciprofloxacin When Combined With an Aminoglycoside in Preventing Severe Infections After Prostate Biopsy.”

Urology 2015 epub. PMID: 25863839.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25863839

Loeb S. Editorial comment on

“Prevalence and predictive factors of harboring fluoroquinolone-resistant and extended-spectrum β-lactamase-producing rectal flora in Hong Kong Chinese men undergoing transrectal ultrasound-guided prostate biopsy.”

Urology 2015; 85: 21-2. PMID 25530360

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530360

Loeb S. Editorial Comment on:

“Outcomes of Fecal Carriage of Extended-Spectrum β-Lactamase After Transrectal Ultrasound-Guided Biopsy of the Prostate.”

Urology 2014 epub. PMID 25239260.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25239260

Davuluri M, Loeb S.

“Prevalence of Infections Associated with Prostate Biopsy.”

Reviews in Urology 2014; 16: 156. PMID: 25337051.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25337051

Loeb S. Editorial Comment on

“Incidence and management of extended-spectrum beta-lactamase and quinolone-resistant Escherichia coli infections after prostate biopsy.”

Urology 2014; 84: 1006-7. PMID: 25443895.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25443895

Loeb S.

“Is Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Ready for ‘Prime Time’?”

European Urology 2014 Nov epub. PMID: 25465339.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25465339

Loeb S.

“Editorial comment on ‘Current Ability of Multiparametric Prostate MRI and Targeted Biopsy to Improve the Detection of Prostate Cancer’”

Urology Practice 2014 May; 1: 20.

Loeb S.

“Editorial Comment on: Serial Prostate Biopsy and Risk of Lower Urinary Tract Symptoms: Results From a Large, Single-Institution Active Surveillance Cohort.”

Urology 2014; 83 (1): 38-19. PMID: 24246328

Link: http://www.ncbi.nlm.nih.gov/pubmed/24246328

Loeb S.

“Editorial Comment on ‘Screening Rectal Culture to Identify Fluoroquinolone-Resistant Organisms Before Transrectal Prostate Biopsy: Do the Culture Results Between Office Visit and Biopsy Correlate?”

Urology 2013; 82: 71.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23806392

Vellekoop A and Loeb S.

“Editorial Comment on A Single Dose of 240 mg Gentamicin During Transrectal Prostate Biopsy Significantly Reduces Septic Complications.”

Urology 2013 epub August.

Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=23992969

Loeb S.

“Infection after Transrectal Ultrasonography-Guided Prostate Biopsy: Increased Relative Risks after Recent International Travel or Antibiotic Use.”

BJU International June 2012; 109: 1785-6. PMID: 22040375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22040375

Loeb S, Van den Heuvel S, Zhu X, Bangma CH, Schroder FH, and Roobol MH.

“Reply from the Authors re: Alexandre R. Zlotta, Robert K. Nam. To Biopsy or Not to Biopsy- Thou Shall Think Twice.” Eur Urol. In press. DOI:10.1016/j.eururo.2012.01.055: Considerations for Prostate Biopsy Decisions.”

European Urology; 2012 March 8 epub.

Link: http://www.europeanurology.com/article/S0302-2838%2812%2900307-7/fulltext/reply-from-authors-re-alexandre-r-zlotta-robert-k-nam-to-biopsy-or-not-to-biopsy-x02014-thou-shall-think-twice-eur-urol-2012-61-1115-x02013-7

Loeb S.

“Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.”

Urology August 2011; 78: 255. PMID: 21820566.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21820566

Loeb S.

“Prostate Biopsy: A Risk-Benefit Analysis.”

Journal of Urology, March 2010; 183: 852.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20089273

Loeb S, Schaeffer EM, and Epstein JI.

“The Vanishing Prostate Cancer Phenomenon.”

Urology, January 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20079526

Key Papers

Loeb S, Curnyn C, Sedlander E.

“Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.”

European Urology 2016 Jun 6 epub. PMID: 27283215.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

This is the first qualitative study to ask patients their perspectives on Gleason grading, which is a significant source of confusion. The majority of patients agreed that they would prefer to be told they have grade group 1 versus Gleason 6 cancer, and that this would encourage the use of active surveillance.

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

This systematic review of epidemiological, clinical and autopsy studies found a very wide of estimates for prostate cancer overdiagnosis from 1.7-67%. Published estimates of overtreatment vary widely based on patient features and may be declining internationally. Careful patient selection for screening and reducing overtreatment are important to preserve the benefits and reduce the downstream harms of prostate-specific antigen testing.

Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P.

“Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging.”

Journal of the National Cancer Institute (JNCI) 2013 July epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23853055

Imaging is very important for staging of high-risk prostate cancer, but is not recommended for low-risk disease. This study demonstrated that a nationwide Swedish campaign successfully reduced inappropriate imaging for low risk prostate cancer (from 45% to 3%), but also was associated with a slight reduction in appropriate imaging in high-risk patients.

Other Papers

Ciprut SE, Kelly MD, Walter D, Hoffman R, Becker DJ, Loeb S, Sedlander E, Tenner CT, Sherman SE, Zeliadt SB, Makarov DV.

“A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study.”

Urology. 2020 Nov;145:113-119. Epub 2020 Jul 25.PMID: 32721517.

Link: https://pubmed.ncbi.nlm.nih.gov/32721517/

Drangsholt S, Walter D, Ciprut S, Lepor A, Sedlander E, Curnyn C, Loeb S, Malloy P, Winn AN, Makarov DV.

” Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.”

Urologic Oncology 2019 Feb;37(2):145-149. PMID: 30578160.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30578160

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

” Public online reporting from a nationwide population-based clinical prostate cancer register”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

“Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869

Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P.

“Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.”

Journal of Surgical Oncology. 2016 Aug 11 epub. PMID: 27511833.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27511833

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.”

European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871

Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.”

BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298

Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P.

“Upper Limit of Cancer Extent on Biopsy Defining Very Low Risk Prostate Cancer.”

BJU International 2014, July epub. PMID: 25053197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25053197

Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, and Stattin P.

“Nationwide Population-Based Study of Prostate Cancer Stage Migration Between and Within Clinical Risk Categories.”

Scandinavian Journal of Urology 2014 March epub. PMID: 24581522

Link: http://www.ncbi.nlm.nih.gov/pubmed/24611795

McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, Yang X, and Catalona WJ.

“Outcomes in Patients with Gleason Score 8-10 Prostate Cancer: Relation to Preoperative PSA Level.”

BJU International June 2012; 109: 1764-9. PMID: 22017732.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22017732

Loeb S, Carvalhal GF, Kan D, Desai A, and Catalona WJ.

“External Validation of the Cancer of the Prostate Risk Assessment (CAPRA) Score in a Single-Surgeon Radical Prostatectomy Series.”

Urologic Oncology: Seminars and Original Investigations, September 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20822930

Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC.

“What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?”

Urology 2009, Nov 19 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19931898

Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, and Catalona WJ.

“Outcomes of Radical Prostatectomy for Patients with Clinical Stage T1a and T1b Disease.”

BJU International, February 2009 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/19239451

Loeb S, Hernandez DH, Mangold LA, Humphreys EB, Agro M, Walsh PC, Partin AW, and Han M.

“Progression after Radical Prostatectomy for Men in their Thirties Compared to Older Men.”

BJU International, June 2008; 101: 1503.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18341626

Loeb S, Roehl KA, Thaxton CS, and Catalona WJ.

“Combined Prostate-Specific Antigen Density and Biopsy Features to Predict ‘Clinically Insignificant’ Prostate Cancer.”

Urology, July 2008; 72: 143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18436287

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology, January 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013

Graif T, Yu Y, Loeb S, Gashti SN, Griffin S, Han M, Roehl KA, Suarez BK, and Catalona WJ.

“Underdiagnosis and Overdiagnosis of Prostate Cancer.”

Journal of Urology 2007; 178: 88.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17499308

Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ.

“Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.”

Urology 2007; 70: 1117.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology, March 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576

Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ.

“Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression”

Urology, July 2006; 68: 99.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410

Reviews/Editorials

Loeb S.

“Is Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Ready for ‘Prime Time’?”

European Urology 2014 Nov epub. PMID: 25465339.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25465339

Loeb S.

“Editorial comment on ‘Current Ability of Multiparametric Prostate MRI and Targeted Biopsy to Improve the Detection of Prostate Cancer’”

Urology Practice 2014 May; 1: 20.

Loeb S and Partin AW.

“Imaging Utilization for the Staging of Clinically Localized Prostate Cancer.”

Reviews in Urology 2011; 13: 63. PMID: 21845110.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155872/

Loeb S.

“Editorial Comment on ‘Impact of Positive Apical Surgical Margins on Likelihood of Biochemical Recurrence After Radical Prostatectomy.”

Journal of Urology, December 2009; 182: 2701.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19836758

Loeb S and Catalona WJ.

“What is the prognostic impact of positive surgical margins in surgically treated prostate cancer?”

Nature Clinical Practice Urology, August 2006; 3: 418.

Link: http://www.nature.com/nrurol/journal/v3/n8/full/ncpuro0549.html

Active Surveillance ▼

Treatment ▼

Post-Treatment ▼

Key Papers

Loeb S, Byrne N, Makarov DV, Lepor H, Walter D.

“Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015.”

JAMA. 2018 Jun 5; 319(21):2231-2233. PMID: 29800017

Link: https://www.ncbi.nlm.nih.gov/pubmed/29800017

In the U.S. Veterans Affairs healthcare system, we found a substantial increase in the use of conservative management for low-risk prostate cancer over the past decade. By 2015, 72% of veterans <65 years and 79% ages ≥65 with low-risk prostate cancer were managed conservatively.

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub. PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

We designed a Markov model showing that active surveillance extends life more than watchful waiting, particularly for men with higher risk features, but this is partly offset by decrements in quality of life from delayed treatment. Trade-offs about the intensity of surveillance should be discussed with patients.

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Using nationwide Sweden data, this study showed that by 2014, active surveillance was selected by 91% of very low risk, 74% of low risk and 19% of intermediate risk patients across the country. These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

“Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.”

European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014

This systematic review examined the utility of markers, genetic factors and risk stratification for active surveillance. The patient factors associated with active surveillance outcomes in some studies include age, race, and family history. Multiple studies provide consistent evidence that a lower percentage of free PSA, a higher Prostate Health Index (PHI), a higher PSA density (PSAD), and greater biopsy core involvement at baseline predict a greater risk of progression. During follow-up, serial measurements of PHI and PSAD, as well as repeat biopsy results, predict later biopsy progression. No conclusive data support the use of genetic tests in active surveillance.

Loeb S, Berglund A, Stattin P.

“Population-Based Study of Utilization and Determinants of Active Surveillance and Watchful Waiting for Low- and Intermediate-Risk Prostate Cancer”

Journal of Urology 2013 May 29 epub. PMID: 23727309

Link: http://www.ncbi.nlm.nih.gov/pubmed/23727309

Using nationwide Sweden data, this study showed that from 2007 to 2011, active surveillance was selected by 59% of very low risk, 41% of low risk and 16% of intermediate risk patients across the country. These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

“Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.”

Journal of Urology October 2012; 188: 1131-6. PMID: 22901577.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22901577

Longitudinal measurements of the Prostate Health Index (phi) during active surveillance were a robust predictor of biopsy reclassification (C-index 0.82). These results have since been validated in other surveillance populations. Since PSA kinetics are unreliable and biopsies are invasive, phi offers another non-invasive test that can be used to monitor patients during active surveillance.

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC.

“Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.”

Journal of Clinical Oncology, June 2010; 28: 2810.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20439642

PSA doubling time and PSA velocity are frequently used to monitor patients during active surveillance. Among men in the Johns Hopkins active surveillance program, PSA kinetics during active surveillance were not reliable predictors of adverse pathology on repeat biopsy. This suggests that PSA kinetics should not be used as a trigger for intervention during active surveillance.

Other Papers

Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P.

“Five-Year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer.”

Eur Urol 2014, June epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24993868

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

“Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer.”

Journal of Urology 2013 epub September 23.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24071481

Reviews/Editorials

Loeb S.

” Overactive Surveillance: Is “Conservative” Management for Low-risk Prostate Cancer Too Aggressive?”

Eur Urol. 2019 May epub. PMID:31060823.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31060823

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Loeb S.

“Active Surveillance for Prostate Cancer.”

Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148

Loeb S.

” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.”

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626

Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.”

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693

Tosoian JJ, Carter HB, Lepor A, Loeb S.

“Active surveillance for prostate cancer: current evidence and contemporary state of practice.”

Nature Reviews Urology 2016 Mar 8 epub. PMID: 26954332.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26954332

Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke PL, Schaeffer EM.

“Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.”

American Society of Clinical Oncology Educational Book. 2016;35:e235-45. PMID: 27249729

Link: http://www.ncbi.nlm.nih.gov/pubmed/26954332

Murphy DG, Loeb S.

“Prostate Cancer: Growth of AS in the USA Signals Reduction in Overtreatment.”

Nature Reviews Urology 2015 epub. PMID: 26390970.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26390970

Loeb S.

“Re: Long-Term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer.”

European Urology 2015 Nov; 68: 907. PMID: 26460874.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26460874

Loeb S, Carter HB, Schwartz M, Fagerlin A, Braithwaite RS, Lepor H.

“Heterogeneity in active surveillance protocols worldwide.”

Reviews in Urology 2014;16(4):202-3. PMID: 25548550.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274180/

Loeb S.

“Does Delaying Prostate Cancer Treatment Miss the Window of Curability?”

European Urology 2013 epub Apr 8. PMID: 23619388

Link: http://www.ncbi.nlm.nih.gov/pubmed/23619388

Loeb S and Catalona WJ.

“Counterpoint: the case for active treatment.”

Journal of the National Comprehensive Cancer Network, August 2007; 5: 699.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17692174

Loeb S and Catalona WJ.

“Early versus delayed intervention for prostate cancer: the case for early intervention.”

Nature Clinical Practice Urology, July 2007; 4: 348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17563779

Key Papers

Bratt O, Folkvaljon Y, Hjalm Eriksson M, Akre O, Carlsson S, Drevin L, Franck Lissbrant I, Makarov D, Loeb S, Stattin P.

“Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.”

European Urology 2015 epub. PMID: 25813688.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25813688

Using data from national Swedish registries, this study showed that many healthy men in their seventies live for at least another 10 years. Despite this long life expectancy, men in their seventies with high-risk nonmetastatic prostate cancer often did not receive treatment with radical prostatectomy or radiotherapy, possibly because their life expectancy was underestimated. This study highlights the need for improved clinical decision-making, which should incorporate an assessment of the patient’s life expectancy.

Loeb S, Zhu X, Schroder FH, Roobol MJ.

“Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.”

BJU International epub Sept 21, 2012. PMID: 22998182.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22998182

This study compared the outcomes of prostate cancer treatment between men in the screening and control arms of the European Randomized Study of Prostate Cancer Screening (ERSPC). Men from the screening arm had a significantly higher progression-free survivial, metastasis-free survival, and cancer-specific survival compared to controls. Improved surgical outcomes among screened men appeared to be mediated by the lower tumor volume at diagnosis. These results show that early detection and successful treatment go hand-in-hand.

Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S.

“The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary.”

Journal of Urology epub October 18, 2012. PMID: 23083655.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23083655

A total of 4,478 men underwent anatomical radical retropubic prostatectomy by Dr Patrick C. Walsh at the Johns Hopkins Medical Institutions from 1982-2011. To commemorate the 30th anniversary of the anatomic RRP, the long-term outcomes were examined. The overall 25-year progression-free, metastasis-free and cancer specific survival rates were 68%, 84% and 86%, respectively, although there were significant differences in treatment outcomes between men treated in the pre-PSA and PSA eras. Anatomical RRP continues to represent the gold standard in the surgical management of clinically localized prostate cancer to which alternate treatment options should be compared.

Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC.

“What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?”

Urology 2009, Nov 19 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19931898

Historically most men with D’Amico high-risk prostate cancer (clinical stage ≥T2c, biopsy Gleason score 8-10, or prostate-specific antigen >20 ng/mL) were treated with combined radiation therapy and hormonal therapy. This study shows that surgical treatment for carefully selected high risk patients can result in long-term progression–free survival. At 10 years, biochemical recurrence-free survival was 68%, metastasis-free survival was 84%, and prostate cancer-specific survival was 92%. The 10-year rate of freedom from any hormonal therapy was 71%. Of the 3 high-risk criteria, a biopsy Gleason score of 8-10 (vs ≤7) was the strongest independent predictor of biochemical recurrence, metastases, and prostate cancer death.

Other Papers

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub. PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800.

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/

Loeb S, Salter CA, Nelson CJ, Mulhall JP, Wittmann D.

“A Call to Arms: Increasing Our Understanding of the Impact of Prostate Cancer on the Sexual Health of Partners.”

Journal of Sexual Medicine. 2019 Dec 10 epub. PMID: 31836299.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31836299

Becker DJ, Iyengar AD, Punekar SR, Ng J, Zaman A, Loeb S, Becker KD, Makarov D.

“Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. “

Anticancer Res.2019 May;39(5):2467-2473. PMID: 31092441.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31092441

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

“Public online reporting from a nationwide population-based clinical prostate cancer register.”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561/a>

Loeb S, Meyer C, Krasnova A, Curnyn C, Reznor G, Lepor H, Kibel AS, Trinh QD.

“Risk of Small Bowel Obstruction After Robot-Assisted Versus Open Radical Prostatectomy.”

Journal of Endourology 2016 Sep 11 epub. PMID: 27615204

Link: https://www.ncbi.nlm.nih.gov/pubmed/27615204

Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer B, Thederan I, Heinzer H, Haese A, Salomon G, Budäus L, Michl U, Pehrke D, Stattin P, Bernard J, Klaus B, Pompe RS, Petersen C, Huland H, Graefen M, Schwarz R, Huber W, Loeb S, Schlomm T.

“Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology.”

2016 Nov 22. PMID: 27887941

Link: https://www.ncbi.nlm.nih.gov/pubmed/27887941

Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, Stattin P, Akre O.

“Ninety-Day Postoperative Mortality after Robot-assisted Laparoscopic Prostatectomy and Retropubic Radical Prostatectomy. Nation-wide population-based study.”

BJU International 2016 Jan 13 epub. PMID: 26762928

Link: http://www.ncbi.nlm.nih.gov/pubmed/26762928

Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998

Sun M, Choueiri TK, Hamnvik OR, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.

“Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.”

JAMA Oncology 2015 Dec 23:1-8 epub. PMID: 26720632

Link: http://www.ncbi.nlm.nih.gov/pubmed/26720632

Carlsson S, Drevin L, Loeb S, Widmark A, Frank Lissbrant I, Robinson D, Johansson E, Stattin P, and Fransson P.

“Population-based study of long-term functional outcomes after prostate cancer treatment.”

BJU International 2014 epub. PMID: 25959859.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25959859

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

“Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer.”

Journal of Urology 2013 epub September 23.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24071481

McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, Yang X, and Catalona WJ.

“Outcomes in Patients with Gleason Score 8-10 Prostate Cancer: Relation to Preoperative PSA Level.”

BJU International June 2012; 109: 1764-9. PMID: 22017732.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22017732

O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, and Catalona WJ.

“Delay of Surgery in Men with Low Risk Prostate Cancer.”

Journal of Urology 2011; 185: 2143. PMID: 21496847.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21496847

Carvalhal GF, Griffin CR, Kan D, Loeb S, and Catalona WJ.

“Reducing Blood Loss in Open Radical Retropubic Prostatectomy with Prophylactic Periprostatic Sutures.”

BJU International 2010; 105: 1222.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888968

Loeb S, Epstein JI, Ross AE, Schultz L, Humphreys EB, and Jarow JP.

“Benign Prostate Glands at the Bladder Neck Margin in Robotic vs. Open Radical Prostatectomy.”

BJU International 2010; 104: 1446

Link: http://www.ncbi.nlm.nih.gov/pubmed/20346031

Makarov DV, Loeb S, Landman AB, Nielsen ME, Gross CP, Leslie DL, Penson DF, and Desai RA.

“Regional Variation in Total Cost per Radical Prostatectomy in the Heathcare Cost and Utilization Project Nationwide Inpatient Sample Database.”

Journal of Urology 2010; 183: 1504.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20172559

Thaxton CS, Loeb S, Roehl KA, Kan D, and Catalona WJ.

“Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Programs.”

Urology 2010; 75: 414.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072831/

Loeb S, Carvalhal GF, Kan D, Desai A, and Catalona WJ.

“External Validation of the Cancer of the Prostate Risk Assessment (CAPRA) Score in a Single-Surgeon Radical Prostatectomy Series.”

Urologic Oncology: Seminars and Original Investigations, September 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20822930

Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, and Catalona WJ.

“Outcomes of Radical Prostatectomy for Patients with Clinical Stage T1a and T1b Disease.”

BJU International 2009 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/19239451

Loeb S, Epstein JI, Humphreys EB, and Walsh PC.

“Does Perineural Invasion on Prostate Biopsy Predict Adverse Prostatectomy Outcomes?”

BJU International, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19694710

Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, and Epstein JI.

“Impact of Tertiary Gleason Patterns on Biochemical Recurrence Following Radical Prostatectomy: Proposal for a Modified Gleason Scoring.”

Journal of Urology, August 2009 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19683280

Nguyen PL, Chen MH, Catalona WJ, Alexander BM, Roehl KA, Loeb S, and D’Amico AV.

“Biochemical Recurrence Following Radical Prostatectomy for Prevalent vs. Incident Cases of Prostate Cancer: Implications for Management.”

Cancer 2008 (epub)

Link: http://www.ncbi.nlm.nih.gov/pubmed/18932254

Loeb S, Roehl KA, Helfand BT, and Catalona WJ.

“Complications of open radical retropubic prostatectomy in potential candidates for active monitoring.”

Urology 2008; 72: 887.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18329080

Loeb S, Hernandez DH, Mangold LA, Humphreys EB, Agro M, Walsh PC, Partin AW, and Han M.

“Progression after Radical Prostatectomy for Men in their Thirties Compared to Older Men.”

BJU International, June 2008; 101: 1503.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18341626

Griffin C, Yu X, Loeb S, Desireddi VN, Han M, and Catalona WJ.

“Pathologic Features after Radical Prostatectomy for Potential Candidates for Active Monitoring.”

Journal of Urology 2007; 178: 860.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17631347

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013

Desireddi VN, Roehl KA, Loeb S, Yu X, Griffin C, Kundu S, Han M, and Catalona WJ.

“Progression-Free Survival Rates for Radical Prostatectomy in the PSA Era.”

Urology 2007; 70: 950.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18068453

Loeb S, Smith N, Roehl KA, and Catalona WJ.

“Intermediate-Term Potency, Continence and Survival Outcomes of Radical Prostatectomy for Clinically High-Risk or Advanced Prostate Cancer.”

Urology 2007; 69: 1170.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572209

Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JAV, and Catalona WJ.

“Survival Results in Screen-Detected Prostate Cancer Patients Versus Physician-Referred Patients Treated With Radical Prostatectomy: Early Results.”

Urologic Oncology: Seminars and Original Investigations 2006; 24: 465.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17138126

Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ.

“Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression”

Urology, 2006; 68: 99.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576

Reviews/Editorials

Loeb S.

“Educational intervention in prostate cancer.”

BJU International 2017 Nov; 120(5B):E3. PMID: 29105995

Link: https://www.ncbi.nlm.nih.gov/pubmed/29105995

Lynch J and Loeb S.

“The Role of HIFU in Prostate Cancer.”

Current Oncology Reports, May 2007; 9: 22.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17430694

Loeb S and Catalona WJ.

“Open Radical Retropubic Prostatectomy.”

Urologic Oncology: Seminars and Original Investigations 2007; 25: 494.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18047959

Loeb S and Catalona WJ.

“Counterpoint: the case for active treatment.”

Journal of the National Comprehensive Cancer Network, August 2007; 5: 699.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17692174

Loeb S and Catalona WJ.

“Early versus delayed intervention for prostate cancer: the case for early intervention.”

Nature Clinical Practice Urology, July 2007; 4: 348.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17563779

Loeb S and Schaeffer EM.

“Does Primary Androgen-Deprivation Therapy Improve Survival for Localized Prostate Cancer?”

Aging Health 2008; 4: 451.

Link: http://www.futuremedicine.com/doi/full/10.2217/1745509X.4.5.451

Loeb S, Schaeffer EM, and Epstein JI.

“The Vanishing Prostate Cancer Phenomenon.”

Urology, January 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20079526

Loeb S, Partin AW, and Schaeffer EM.

“Complications of Pelvic Lymphadenectomy: Do the Risks Outweigh the Benefits?”

Reviews in Urology, Winter 2010; 12: 20.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859138/

Loeb S and Partin AW.

“Open versus minimally invasive radical prostatectomy.”

Reviews in Urology, Winter 2010; 12: 20.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859144/

Schaeffer EM, Loeb S, and Walsh PC.

“The Case for Open Radical Prostatectomy.”

Urological Clinics of North America 2010; 37: 49.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20152519

Loeb S.

“Prediction of Outcomes After Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy Gleason Score ≥8 Via Contemporary Multi (≥12)-Core Prostate Biopsy.”

BJU International July 2011; 108: 222. PMID: 21718432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21718432

Tosoian J and Loeb S.

“Radical Retropubic Prostatectomy: Comparison of the Open and Robotic Approaches for Treatment of Prostate Cancer.”

Reviews in Urology 2012; 14: 1-8. PMID: 23172996.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502048/

Loeb S.

“The Age Old Question: Who Benefits From Prostate Cancer Treatment?”

British Journal of Urology International 2013; 1134: 4. PMID: 24330057

Link: http://www.ncbi.nlm.nih.gov/pubmed/24330057

Loeb S.

“Does Delaying Prostate Cancer Treatment Miss the Window of Curability?”

European Urology 2013 epub Apr 8. PMID: 23619388

Link: http://www.ncbi.nlm.nih.gov/pubmed/23619388

Stattin P and Loeb S.

‘To measure is to know. If you cannot measure it, you cannot improve it.’ Statistical Modeling Cannot Compensate for Unmeasured Bias.”

European Urology 2013; June epub

Link: http://www.ncbi.nlm.nih.gov/pubmed/23830142

Loeb S, Montorsi F, Catto JW.

“Future-Proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?”

European Urology 2015 epub. PMID: 25769986.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25769986

Loeb S, Schlomm T, Stattin P.

“Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma.”

European Urology 2015 epub July. PMID: 26238432.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26238432

Loeb S and Schaeffer EM.

“Optimal Therapy in Localized Prostate Cancer: An Unfolding Story.’”

Oncology (Williston Park), September 2009; 23: 843.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19839426

Loeb S and Nadler RB.

“Management of the Complications of External Beam Radiotherapy and Brachytherapy.”

Current Urology Reports, May 2006; 7: 200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16630523

Key Papers

Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, and Walsh PC.

“Can We Stop Prostate Specific Antigen Testing 10 Years After Radical Prostatectomy?”

Journal of Urology August 2011; 186: 500. PMID: 21679999.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21679999

Patients often ask whether it is necessary to continue PSA testing indefinitely after radical prostatectomy. In the Johns Hopkins radical prostatectomy database, 77% of all biochemical recurrences occurred within the first 5 years, 17% from 5-10 years, 6% from 10-15 years and only 1.5% more than 15 years after surgery. For men with an undetectable prostate specific antigen at 10 years the actuarial probability of biochemical recurrence and metastasis at 20 years varied by stage and grade, with no metastases in patients with low-grade disease at prostatectomy. A single patient with an undetectable prostate specific antigen at 10 years died of prostate cancer within 20 years after radical prostatectomy. This suggests that less intense monitoring is possible beyond 10 years, particularly for men with favorable tumor features.

Loeb S, Makarov DV, Schaeffer EM, Humphreys EB, and Walsh PC.

“Prostate-specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.”

Journal of Urology, July 2010; 184: 157.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20483148

In men with newly diagnosed prostate cancer, bone metastases are uncommon at PSA levels <20 ng/ml. However, after radical prostatectomy bone metastases may occur at much lower PSA levels. Among 193 hormone naïve men who developed bone metastases after radical prostatectomy, bone scan conversion occurred at a PSA <10, 10-100 and >100 ng/ml in 26%, 51% and 23% men, respectively.

Other Papers

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub. PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/

Loeb S, Salter CA, Nelson CJ, Mulhall JP, Wittmann D.

“A Call to Arms: Increasing Our Understanding of the Impact of Prostate Cancer on the Sexual Health of Partners.”

Journal of Sexual Medicine. 2019 Dec 10 epub. PMID: 31836299.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31836299

Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P.

“Opioid Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden.”

J Urol. 2019 Jul 17 epub. PMID:31584849

Link: https://www.ncbi.nlm.nih.gov/pubmed/31584849

Banks JA, McGuire BB, Loeb S, Shrestha S, Helfand BT, Catalona WJ.

“Bacteriuria and antibiotic resistance in catheter urine specimens following radical prostatectomy.”

Urologic Oncology 2012, epub Jan 25. PMID: 22285005.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22285005

Loeb S, Schaeffer EM, Chan DW, Carter HB, Walsh PC, and Sokoll LJ.

“Investigation of Human Anti-Mouse Antibodies As Potential Cause of Postprostatectomy PSA Elevation.”

Urology, May 2009; 73: 947.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19394489

Loeb S, Roehl KA, Viprikasit DP, and Catalona WJ.

“Long-Term Rates of Undetectable PSA with Initial Observation and Delayed Salvage Radiotherapy after Radical Prostatectomy.”

European Urology, July 2008; 54: 88.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18400368

DIGITAL HEALTH

Social Media ▼

Telemedicine and Digital Technology ▼

Dubin JM, Wyant WA, Balaji NC, Ong WL, Kettache RH, Haffaf M, Zouari S, Santillan D, Autrán Gómez AM, Sadeghi-Nejad H, Loeb S, Borin JF, Gomez Rivas J, Grummet J, Ramasamy R, Teoh JYC.

“Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study.”

J Med Internet Res. 2020 Nov 5;22(11):e21875. PMID: 33031047

Link: https://pubmed.ncbi.nlm.nih.gov/33031047/

Rodriguez Socarrás M, Loeb S, Teoh JY, Ribal MJ, Bloemberg J, Catto J, N’Dow J, Van Poppel H, Gómez Rivas J.

“Telemedicine and Smart Working: Recommendations of the European Association of Urology.”

Eur Urol. 2020 Dec;78(6):812-819. PMID: 32654801

Link: https://pubmed.ncbi.nlm.nih.gov/32654801/

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R, O’Brien T, Odisho AY, Powles T, Skolarus TA, Smith AB, Szabados B, Klaassen Z, Spratt DE.

“The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.”

Eur Urol. 2020 Nov;78(5):731-742. PMID: 32893062.

Link: https://pubmed.ncbi.nlm.nih.gov/32893062/

Key Papers

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.
Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

“Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.“

European Urology. 2015 Dec 29 epub. PMID: 26743040

Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040

A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.

Other Papers

Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P.

“Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.”

J Natl Cancer Inst. 2017 Aug 1;109(8). PMID: 29117385

Link: https://www.ncbi.nlm.nih.gov/pubmed/29117385

Loeb S, Stattin P.

“Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma.”

European Urology 2016 Jul 16 epub. PMID: 27436160.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27436160

Loeb S, Lambe M, Stattin P.

“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology 2021; S0090-4295(21)00266-1. PMID: 33775787.

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub. PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November. PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463

Loeb S, Semins MJ, and Matlaga BR.

“Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.”

Urology, August 2012; 80: 474. PMID: 22857764.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22857764

Gupta AD, Loeb S, Stec A, and Wang MH.

“Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis.”

Urology December 2011; 78: 1414-6. PMID: 21676451.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21676451

Rubenstein RA, Zhao LC, Loeb S, Shore DM, and Nadler RB.

“Prestenting Improves Ureteroscopic Stone-Free Rates.”

J Endourol, November 2007; 21: 1277.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18042014

Loeb S, Vardi IY, and Nadler RB.

“Contemporary Management of Urosepsis: Updated Critical Care Guidelines.”

Contemporary Urology, July 2005

Nickel JC, Gorin MA, Alan W P, Loeb S, Ellen S, Chancellor MB, Assimos DG, Brawer MK, Brucker BM.

“Best of the 2016 AUA Annual Meeting: Highlights From the 2016 American Urological Association Annual Meeting, May 6-10, 2016, San Diego, CA.”

Reviews in Urology 2016;18(3):159-173. PMID: 27833468.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27833468

Nickel JC, Gorin MA, Partin AW, Assimos D, Brawer M, Nicolai H, Chancellor MB, Goggins Á, Loeb S, Shapiro E.

“Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.”

Reviews in Urology 2015;17(3):179-89. PMID: 26543434

Link: http://www.ncbi.nlm.nih.gov/pubmed/26543434

Loeb S.

“Prostate Cancer Screening Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014.”

Reviews in Urology 2014; 16: 90. PMID: 25009450.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080855/

Loeb S, Borin JF.

“Advances in Localized Prostate Cancer: Highlights From the 2012 Friends of Israel Urological Symposium, July 3-5, 2012, Tel Aviv, Israel.”

Reviews in Urology 2013; 15: 82.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784972/

Loeb S, Assimos D, Chancellor MB, Nickel JC, Brawer MK, Kern AJ, Partin AW.

“Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA..”

Reviews in Urology 2013; 15: 72.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784971/

Nickel JC, Partin AW, Nirmal J, Chancellor MB, Loeb S, Brawer MK, Assimos D, and Shapiro E.

“Best of 2012 AUA Annual Meeting: Highlights from the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.”

Reviews in Urology 2012; 14: 90-103. PMID: 23526762

Link: http://www.ncbi.nlm.nih.gov/pubmed/23526762

Loeb S.

“Prostate Cancer Screening and Surgical Management of Localized Disease: Highlights from the 27^th Annual Congress of the European Association of Urology, February 24-28, 2012, Paris, France.”

Reviews in Urology 2012; 14: 87-9. PMID: 23526727

Link: http://www.ncbi.nlm.nih.gov/pubmed/23526727

Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A.

“Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.”

BJU International 2012; 109 Suppl 2: 1-7. PMID: 22257098.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22257098

Brawer MK, Loeb S, Partin AW, Nirmal J, Chancellor MB, Nickel JC, Rajfer J, Shapiro E, and Roehrborn CG.

“Best of the AUA Annual Meeting: Highlights from the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.”

Reviews in Urology 2011; 13: 151-72. PMID: 22114546.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725309/

Loeb S and Borin JF.

“Innovation in Endourology and Minimally Invasive Surgery. Highlights from the 29^th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan.”

Reviews in Urology 2012; 14: 28-30. PMID: 23172997.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502049/

Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, and Shapiro E.

“Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.”

Reviews in Urology, Spring 2009; 11: 82.

Key Papers

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

“Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.”
European Urology. 2015 Dec 29 epub. PMID: 26743040

Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040

A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

Other Papers

Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P.

“Opiod. Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden”

J Urol. 2019 Jul 17 epub. PMID:31584849

Link: https://www.ncbi.nlm.nih.gov/pubmed/31584849

Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P.

“Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.”

J Natl Cancer Inst. 2017 Aug 1;109(8). PMID: 29117385

Link: https://www.ncbi.nlm.nih.gov/pubmed/29117385

Loeb S, Stattin P.

“Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma.”

European Urology 2016 Jul 16 epub. PMID: 27436160.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27436160

Loeb S, Lambe M, Stattin P.

“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

Loeb S, Lambe M, Stattin P.
“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Loeb S.

“Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.”

Urology August 2011; 78: 255. PMID: 21820566.

Dubin JM, Wyant WA, Balaji NC, Ong WL, Kettache RH, Haffaf M, Zouari S, Santillan D, Autrán Gómez AM, Sadeghi-Nejad H, Loeb S, Borin JF, Gomez Rivas J, Grummet J, Ramasamy R, Teoh JYC.

“Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study.”

J Med Internet Res. 2020 Nov 5;22(11):e21875. PMID: 33031047.

Link: https://pubmed.ncbi.nlm.nih.gov/33031047/

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R, O’Brien T, Odisho AY, Powles T, Skolarus TA, Smith AB, Szabados B, Klaassen Z, Spratt DE.

“The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.”

Eur Urol. 2020 Nov;78(5):731-742. PMID: 32893062.

Link: https://pubmed.ncbi.nlm.nih.gov/32893062/

Ong WLK, Lechmiannandan S, Loeb S, Teoh JY.

“Urologic Services in Public Hospitals Suffered a Greater Detriment Than Private Hospitals During the Battle of COVID-19.”

Urology. 2020 Oct; 144:269-270. Epub 2020 Jul 18.PMID: 32687841.

Link: https://pubmed.ncbi.nlm.nih.gov/32687841/

Rodriguez Socarrás M, Loeb S, Teoh JY, Ribal MJ, Bloemberg J, Catto J, N’Dow J, Van Poppel H, Gómez Rivas J.

“Telemedicine and Smart Working: Recommendations of the European Association of Urology”

Eur Urol. 2020 Dec;78(6):812-819. PMID: 32654801.

Link: https://pubmed.ncbi.nlm.nih.gov/32654801/

Heldwein FL, Loeb S, Wroclawski ML, Sridhar AN, Carneiro A, Lima FS, Teoh JY.

“A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic.”

Eur Urol Focus. 2020 Jun 5 epub. PMID: 32532703.

Link: https://pubmed.ncbi.nlm.nih.gov/32532703/

Teoh JY, Ong WLK, Gonzalez-Padilla D, Castellani D, Dubin JM, Esperto F, Campi R, Gudaru K, Talwar R, Okhunov Z, Ng CF, Jain N, Gauhar V, Wong MC, Wroclawski ML, Tanidir Y, Rivas JG, Tiong HY, Loeb S; UroSoMe Working Group.

“A Global Survey on the Impact of COVID-19 on Urological Services.”

Eur Urol. 2020 May 26 epub. PMID: 32507625.

Link: https://pubmed.ncbi.nlm.nih.gov/32507625/

Davuluri M, Barry E, Loeb S, Watts K.

“Does it Exist at AUA Plenary Sessions?”

Urology. 2020 May 18 epub. PMID: 32439553.

Link: https://pubmed.ncbi.nlm.nih.gov/32439553/

Loeb S, Byrne NK, Thakker S, Walter D, Katz MS.

“#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology.”

European Urology Focus. 2020 Apr 12:S2405-4569(20)30093-6. PMID: 32295754

Link: https://pubmed.ncbi.nlm.nih.gov/32295754/

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/

Dr. Stacy Loeb MD, MSc, PhD (Hon)

Publications

Prostate Cancer

Key Papers

Other Original Articles

Reviews/Editorials

Key Papers

Other Original Articles

Reviews/Editorials

Key Papers

Other Original Articles

Reviews/Editorials

Key Papers

Other Original Articles

Reviews/Editorials

Key Papers

Other Original Articles

Reviews/Editorials

Key Papers

Other Papers

Reviews/Editorials

Key Papers

Other Original Articles

Other Papers

Reviews/Editorials

Key Papers

Other Papers

Reviews/Editorials

Key Papers

Other Papers

DIGITAL HEALTH

OTHER TOPICS

Key Papers

Other Papers

Key Papers

Other Papers